ENTR 601 45
Alternative Names: ENTR-601-45Latest Information Update: 16 Oct 2024
Price :
$50 *
At a glance
- Originator Entrada Therapeutics
- Class Drug conjugates; Oligonucleotides
- Mechanism of Action Nucleic acid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 09 Oct 2024 Pharmacodynamics data from preclinical trial in Duchenne muscular dystrophy released by Entrada Therapeutics
- 13 Mar 2024 Entrada Therapeutics plans to file an IND application for Duchenne muscular dystrophy in the fourth quarter of 2024
- 13 Mar 2024 Entrada Therapeutics plans a phase II trial for Duchenne muscular dystrophy